We recently published our article 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at SOPHiA GENETICS S.A. (NASDAQ:SOPH) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

10 Best Cheap AI Medicine Stocks to Buy Now

6. SOPHiA GENETICS S.A. (NASDAQ:SOPH)

SOPHiA GENETICS S.A. (NASDAQ: SOPH) ranks sixth as a small-cap precision medicine company using artificial intelligence to analyze complicated genomic and medical information. Shares traded near $8.09, while the market capitalization stood at approximately $529 million.

The company’s cloud-based platform helps hospitals, laboratories and pharmaceutical organizations interpret genomic data. Its technology is particularly relevant to precision oncology, where understanding the molecular characteristics of a tumor can help doctors select more appropriate treatments.

Healthcare institutions can generate enormous volumes of biological data but may lack the internal technology required to analyze it consistently. The platform is designed to convert that raw information into insights that can support diagnosis, drug development and treatment selection. As more hospitals adopt genomic testing, demand for AI-powered clinical data analysis could expand.

Second-quarter 2026 revenue increased 27% to $23.3 million. Reported gross margin reached 64.6%, while adjusted gross margin was 72.1%. The adjusted EBITDA loss improved 27% to $8.8 million. The complete quarterly performance was published in the company’s financial announcement.

The revenue growth is encouraging, but the company remains far from conventional profitability. Its quarterly net loss totaled $22.4 million, nearly equal to its revenue for the period. This creates an obvious need to continue controlling expenses and preserving cash.

Its relatively small market capitalization creates substantial multibagger potential if the platform becomes a widely adopted part of precision medicine. Still, investors must monitor cash usage, customer growth and dilution carefully. The technology addresses a genuine healthcare need, but the company must prove that strong revenue growth can eventually translate into sustainable earnings.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.